Inosine 5-monophosphate dehydrogenase II, a key enzyme in the de novo synthesis of purine nucleotides, is expressed in prostate tumors and prostate cancer cells. AVN944 is a new, specific, noncompetitive IMPDH inhibitor. In this study, we investigated the effects of IMPDH inhibitor AVN944 on LNCaP, CWR22Rv1, DU145 and PC-3 human prostate cancer cells. AVN944 inhibited proliferation of these 4 prostate cancer cell lines and was associated with cell cycle G1 arrest of LNCaP cells and S-phase block of androgen-independent CWR22Rv1, DU145 and PC-3 cells. AVN944 induced caspase-dependent and caspase-independent cell death in LNCaP, CWR22Rv1, and DU145 cells. AVN944 induced expression of p53-target proteins Bok, Bax and Noxa in androgenresponsive cell lines and suppressed expression of survivin in prostate cancer cells regardless of their androgen sensitivity. AVN944 also induced differentiation of androgen-independent prostate cancer cells as indicated by morphological changes and increased expression of genes coding for prostasomal proteins, keratins and other proteins, including tumor suppressor genes MIG-6 and NDRG1. AVN944-differentiated androgen-independent DU145 and PC-3 cells are sensitized to TRAIL-induced apoptosis as demonstrated by induction of caspases and PARP cleavage. In summary, AVN944 inhibited the growth of human prostate cancer cells by inducing cell cycle arrest, cell death as well as differentiation. AVN944 is a novel, promising therapeutic agent that might be combined with other agents for treatment of human prostate cancer. ' 2008 Wiley-Liss, Inc.Key words: AVN944; IMPDH; prostate cancer; cell death; differentiation; TRAIL Prostate cancer is the most commonly diagnosed malignancy in men and is second only to lung cancer as the cause of cancer death in males. In 2008, it has been estimated that 186,320 men in the United States will be diagnosed with prostate cancer, and that 28,660 will die from the disease.1 Unfortunately, there is no cure for locally advanced or metastatic prostate cancer. Therefore, it is imperative that new strategies for the effective management and/ or treatment of this disease be found.Several lines of research have identified inosine 5-monophosphate dehydrogenase (IMPDH) as an attractive target for pharmacological intervention. IMPDH is a key enzyme in the de novo synthesis of purine nucleotides. Two isoforms of IMPDH were identified in humans, type I and type II.2 Each of the genes encodes a protein of 514 amino acids, with high homology between the isoforms (84% amino acid identity).Jackson et al. 3 and Weber 4 linked IMPDH with proliferation and malignancy and observed that the enzyme is upregulated in rapidly proliferating tumor cells. Elevated activity of IMPDH is primarily caused by upregulation of IMPDH II. Allison et al. 5 demonstrated that lymphocytes in particular are dependent on the de novo pathways of nucleotide biosynthesis, making IMPDH a target for immunosuppressive therapy. IMPDH I was also recently identified as an antiangiogenic drug target by Ch...